Advertisement

Conservative Treatment: Pharmacological Therapy

  • Hisashi HidakaEmail author
Chapter

Abstract

Current pharmacological therapy for the management of variceal hemorrhage consists of splanchnic vasoconstrictors (vasopressin and analogues, somatostatin and analogues, nonselective beta-blockers [NSBBs]), splanchnic vasodilators (nitrates and angiotensin receptor blockers), gastric acid-suppressive drugs, and prophylactic antibiotics. Several studies have shown that NSBBs are effective in decreasing portal venous pressure and the risk of variceal hemorrhage. However, approximately 15% of patients with risky varices have contraindications to the use of NSBBs. Furthermore, a meta-analysis showed that NSBBs did not significantly reduce the first variceal hemorrhage in patients with small varices. Further studies are warranted to determine the potential of drugs (besides NSBBs) as an alternative or adjunct to NSBBs.

Keywords

Esophagogastric varices Portal hypertension Cirrhosis Nonselective beta-blockers Mortality 

References

  1. 1.
    North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–9.CrossRefGoogle Scholar
  2. 2.
    D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.CrossRefGoogle Scholar
  3. 3.
    Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding—unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008;47:1764–72.CrossRefGoogle Scholar
  4. 4.
    de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefGoogle Scholar
  5. 5.
    Turnes J, Garcia-Pagan JC, Abraldes JG, et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506–12.CrossRefGoogle Scholar
  6. 6.
    Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.CrossRefGoogle Scholar
  7. 7.
    Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50:825–33.CrossRefGoogle Scholar
  8. 8.
    Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–41.CrossRefGoogle Scholar
  9. 9.
    Bañares R, Albillos A, Rincón D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35:609–15.CrossRefGoogle Scholar
  10. 10.
    Garcia-Pagán JC, Barrufet M, Cardenas A, et al. Management of gastric varices. Clin Gastroenterol Hepatol. 2014;12:919–28.CrossRefGoogle Scholar
  11. 11.
    Mishra SR, Sharma BC, Kumar A, et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol. 2011;54:1161–7.CrossRefGoogle Scholar
  12. 12.
    Angelico M, Carli L, Piat C, et al. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology. 1997;113:1632–9.CrossRefGoogle Scholar
  13. 13.
    Bolognesi M, Balducci G, Garcia-Tsao G, et al. Complications in the medical treatment of portal hypertension. Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford, UK: Blackwell Science; 2001. p. 180–203.Google Scholar
  14. 14.
    Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med. 1996;334:246–54.CrossRefGoogle Scholar
  15. 15.
    Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745–50.CrossRefGoogle Scholar
  16. 16.
    Schneider AW, Friedrich J, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334–9.CrossRefGoogle Scholar
  17. 17.
    Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026–33.CrossRefGoogle Scholar
  18. 18.
    Hidaka H, Kokubu S, Nakazawa T, et al. New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. Hepatol Res. 2007;37:1011–7.CrossRefGoogle Scholar
  19. 19.
    Hidaka H, Nakazawa T, Shibuya A, et al. Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial. J Gastroenterol. 2011;46:1316–23.CrossRefGoogle Scholar
  20. 20.
    Tandon P, Abraldes JG, Berzigotti A, et al. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273–82.CrossRefGoogle Scholar
  21. 21.
    Cotton PB, Williams CB. Practical gastrointestinal endoscopy. Cambridge, MA: Blackwell Science; 1996.Google Scholar
  22. 22.
    Shaheen NJ, Stuart E, Schmitz SM, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology. 2005;41:588–94.CrossRefGoogle Scholar
  23. 23.
    Hidaka H, Nakazawa T, Wang G, et al. Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial. J Gastroenterol. 2012;47:118–26.CrossRefGoogle Scholar
  24. 24.
    Campbell MS, Obstein K, Reddy KR, et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci. 2008;53:394–8.CrossRefGoogle Scholar
  25. 25.
    van Vlerken LG, Huisman EJ, van Hoek B, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Investig. 2012;42:760–7.CrossRefGoogle Scholar
  26. 26.
    Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26:1372–8.CrossRefGoogle Scholar
  27. 27.
    Bernard B, Cadranel JF, Valla D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995;108:1828–34.CrossRefGoogle Scholar
  28. 28.
    Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207–12.CrossRefGoogle Scholar
  29. 29.
    Bernard B, Grangé JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology, Internal MedicineKitasato University School of MedicineSagamiharaJapan

Personalised recommendations